Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 18/20 | 0.70 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190515 | 0.85 | SYK (0.61) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL190333 | 0.83 | SYK (0.49) | SYKAURKAMAPK8AURKBJAK2 | |
| SCHEMBL191238 | 0.83 | SYK (0.54) | SYKAURKAMAPK8AURKBJAK2 | |
| SCHEMBL189926 | 0.83 | SYK (0.46) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL656760 | 0.82 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL30009410 | 0.82 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL30009889 | 0.82 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL656578 | 0.82 | SYK (1.00) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL13007743 | 0.81 | SYK (0.72) | SYKAURKAMAPK8AURKBCDK19 | |
| SCHEMBL657903 | 0.80 | SYK (0.71) | SYKAURKAMAPK8AURKBCDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1814878-B1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| EP-1814878-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006068770-A1 | SPIRO-2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | SYK 1168/4885AURKA 2921/4885MAPK8 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.